This LAT1 inhibitor, JPH203 (nanvuranlat; IC50 0.14 μM, no transport via LAT2) 120, underwent a series of in vitro and in vivo studies confirming its potential for a pan-cancer therapeutic agent 26. Here, SLC7A5 is linked to cancer.